Navigation Links
EASL-AASLD Special Conference on Therapy of Hepatitis C
Date:6/28/2012

The European Association for the Study of the Liver (EASL), together with the American Association for the Study of Liver Diseases (AASLD), will be holding an exciting "Special Conference" dedicated to the timely topic of:

Therapy of Hepatitis C: Clinical Application and Drug Development

During the three days of the conference held from 14-16 September 2012 in Prague, Czech Republic leading international Hepatitis C experts will highlight and address a series of lectures, and participate in interactive debates on hop topics in Hepatitis C. Case presentations and parallel interactive sessions will take place and space will be reserved for poster presentations of original works in the field.

The EASL-AASLD Special Conference provides an opportunity to keep abreast of the latest developments in this rapidly advancing field. The programme has been designed to provide adequate time for discussion and networking and will address a variety of areas including:

  • Global scale intervention and control of HCV
  • Prospects for a preventive HCV vaccine
  • Review of new drug treatments in development such as Nonnucleoside inhibitors of HCV RNA polymerase, NS5A inhibitors, and Cyclophylin inhibitors
  • Effectiveness of triple combinations in cirrhotics

Prof. Dr. Heiner Wedemeyer, a former EASL Secretary General and one of the Special Conference organisers, said a major discussion point at the conference will deal with the real-world use of new direct-acting antivirals (DAAs):

"We will discuss how to manage the side-effects of DDAs in real-world settings, and also their efficacy in populations not treated in pivotal registration trials. This is extremely important for physicians who are starting to use the drugs, particularly in terms of which patients should now be treated," said Prof. Dr. Heiner Wedemeyer.

Moreover, Prof. Dr. Wedemeyer said perspectives on Interferon (IFN) free treatment regimens will be extremely exciting: "After more than 25 years, we can now develop therapies that will not require IFN-alpha, which causes many side-effects and is also very expensive. We are experiencing a paradigm shift in the therapy of hepatitis C. This conference will also be very important for the development of new guidelines in Europe!"


'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-207-331-5472
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. High Blood Pressure May Be Especially Lethal for Blacks
2. Internal medicine physician specialists release policy paper on reforming Medicaid
3. Being left out puts youths with special needs at risk for depression
4. Gastroenterology special issue focuses on new directions of viral hepatitis care and research
5. Specialized care by experienced teams cuts death and disability from bleeding brain aneurysms
6. Prenatal exposure to pollution especially dangerous for children with asthma
7. Hospital volume and surgeon specialty influence patient outcomes
8. Ethics should drive health policy reform, especially with physician-owned specialty hospitals
9. U.S.A. Hurdle Specialist Kellie Wells has Joined Elite Athletes Tiger Woods, Hines Ward and Takaishi Saito in Using Cell Therapy
10. Nassau County’s Special Districts and Service Providers Mapped for the First Time
11. Elsevier organizes label-free technologies conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... CT (PRWEB) , ... March 22, 2017 , ... ... historic plan to cure Rett Syndrome, a devastating neurological disorder that afflicts 350,000 ... MECP2, located on the X chromosome, and almost exclusively strikes females. Following ...
(Date:3/22/2017)... ... 22, 2017 , ... University Orthopedics (UOI) today announced the ... Hand, Upper Extremity and Microvascular Surgery at Newport Hospital. Dr. Bragdon specializes in ... and Hand Surgery. , As the leader of comprehensive orthopedic care in ...
(Date:3/22/2017)... Antonio, TX (PRWEB) , ... March 22, 2017 ... ... certified medical imaging core lab with extensive therapeutic experience and operational excellence in ... phase II immuno-oncology clinical trial for the treatment of non-small cell lung cancer ...
(Date:3/22/2017)... ... 22, 2017 , ... The Vanderbeck Agency, a Long Island firm providing insurance, ... embarking on a combined charity effort with the Great Neck Breast Cancer Coalition to ... the Great Neck Breast Cancer Coalition has worked to support breast cancer patients in ...
(Date:3/22/2017)... , ... March 22, 2017 , ... Schneider Insurance and ... and business owners throughout the Yellowstone Valley region, is launching a charity event aimed ... and botanical garden in all of Montana State, and is home to a broad ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 2017 Under the impetus of the ... size increased year by year at the CAGR ... the market size will maintain the growth rate ... RMB140 billion in 2021, thanks to severe aging, ... biological agents and supporting policies. At present, ...
(Date:3/22/2017)...  CANTEL MEDICAL CORP. (NYSE: CMD ) announced ... will be presenting at the 16 th Annual Needham ... in New York . The formal presentation ... ET. In addition, management will be available for separate one-on-one ... webcast will be available via the investor relations page of ...
(Date:3/22/2017)... 22, 2017 Research and Markets has announced ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... around 7.1% over the next decade to reach approximately $129.81 billion ... and forecasts for all the given segments on global as well ...
Breaking Medicine Technology: